Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Xeljanz
Xeljanz
Pfizer's Xeljanz drops off top June TV spenders list—and Gilead's Biktarvy fills the void
Fierce Pharma
Thu, 07/11/19 - 09:45 am
AbbVie
Humira
Gilead Sciences
Biktarvy
Truvada
Pfizer
Xeljanz
television ads
DTC ads
Pfizer announces results from XELJANZ XR ORAL Shift study
Pharmaceutical Business Review
Thu, 06/13/19 - 10:05 am
Pfizer
Xeljanz
clinical trials
rheumatoid arthritis
EMA imposes formal limit on Xeljanz prescription as regulators continue to review safety concerns
Endpoints
Sat, 05/18/19 - 08:47 pm
EMA
Pfizer
Europe
Xeljanz
post-marketing studies
EMA sounds its own safety alarm for Pfizer blockbuster, but they’re also not forcing a limit on dosing — yet
Endpoints
Wed, 03/20/19 - 08:14 pm
Pfizer
Xeljanz
Europe
EMA
rheumatoid arthritis
R&D round-up: Non-opioid painkiller space heats up
Pharmaforum
Sat, 03/16/19 - 12:38 pm
painkillers
opioids
non-opioid pain treatments
Merck
Kings College London
Pfizer
Eli Lilly
tanezumab
Xeljanz
AbbVie and Pfizer return to the top of pharma's TV spending list for February
Fierce Pharma
Wed, 03/6/19 - 11:36 am
AbbVie
Humira
Pfizer
Xeljanz
television ads
DTC ads
Pfizer’s blockbuster safety issue jumps the Atlantic as EMA launches its own review of Xeljanz
Endpoints
Fri, 03/1/19 - 12:07 pm
Pfizer
Europe
JAK inhibitors
Xeljanz
Does Pfizer's Xeljanz share its CV safety questions with burgeoning JAK class?
Fierce Pharma
Sat, 02/23/19 - 04:32 pm
Pfizer
Xeljanz
JAK inhibitors
Pfizer drops higher dose treatment arm in Xeljanz post-marketing study due to safety issues
CP Wire
Wed, 02/20/19 - 11:52 am
Pfizer
Xeljanz
post-marketing studies
FDA
rheumatoid arthritis
ulcerative colitis
Pfizer drops higher dose treatment arm in Xeljanz post-marketing study due to safety issues
Wed, 02/20/19 - 11:51 am
Pfizer
Xeljanz
post-marketing studies
FDA
rheumatoid arthritis
ulcerative colitis
Pfizer's Xeljanz jumps into ulcerative colitis fray with best-case FDA approval
Fierce Pharma
Thu, 05/31/18 - 10:58 am
Pfizer
Xeljanz
FDA
ulcerative colitis
Up-and-coming Pfizer, AbbVie drugs set to threaten Amgen, Celgene: analyst
Fierce Pharma
Wed, 05/23/18 - 09:54 am
Pfizer
Xeljanz
AbbVie
Upadacitinib
JAK inhibitors
Amgen
Enbrel
Celgene
Merck gets a lift, Pfizer a ding as analysts assess immuno-oncology, M&A outlook
Fierce Pharma
Fri, 04/6/18 - 11:49 am
Merck
Pfizer
immuno-oncology
M&A
Keytruda
Prevnar
Ibrance
Xeljanz
Xtandi
Pfizer Gets FDA Panel Backing for New Indication for Xeljanz
Yahoo/Zacks.com
Fri, 03/9/18 - 10:50 am
Pfizer
FDA
advisory panels
Xeljanz
ulcerative colitis
Pfizer takes on Novartis, Lilly with Xeljanz psoriatic arthritis approval
Fierce Pharma
Fri, 12/15/17 - 11:27 pm
Pfizer
Novartis
Eli Lilly
Xeljanz
psoriatic arthritis
Humira may spend most on TV, but Xeljanz, Taltz and Breo notch highest view rates
Fierce Pharma
Thu, 08/10/17 - 10:47 am
Humira
Xeljanz
Taltz
Breo
drug ads
television ads
DTC ads
Lilly's baricitinib setback gives Pfizer's Xeljanz a clear shot at newer rivals
Fierce Pharma
Wed, 07/26/17 - 10:33 pm
Eli Lilly
baricitinib
Pfizer
Xeljanz
bloodthinners
Pfizer’s Xeljanz: Results from the ORAL Strategy
Market Realist
Mon, 06/26/17 - 10:38 pm
Pfizer
Xeljanz
rheumatoid arthritis
Pfizer Announces Approval By The China Food And Drug Administration Of XELJANZ®, The First Oral JAK Inhibitor For Adult Patients With Moderately To Severely Active Rheumatoid Arthritis
Yahoo
Thu, 03/16/17 - 09:45 am
Pfizer
China
Xeljanz
rheumatoid arthritis
Pfizer Reports Top-Line Results for Rheumatoid Arthritis Treatment Study
Yahoo/GuruFocus
Mon, 02/27/17 - 10:11 pm
Pfizer
rheumatoid arthritis
Xeljanz
Pages
« first
‹ previous
1
2
3
4
next ›
last »